Core Viewpoint - Shenzhen Jieput Optoelectronics Co., Ltd. has announced the first grant of restricted stock under its 2025 Restricted Stock Incentive Plan, with a total of 380,000 shares to be granted at a price of 36 yuan per share on August 26, 2025, to 93 eligible participants [1][11]. Summary by Sections Restricted Stock Grant Details - The grant date for the restricted stock is set for August 26, 2025 [1]. - A total of 380,000 shares will be granted, representing 0.40% of the company's total share capital of 95,049,423 shares [1][8]. - The stock incentive plan is classified as a second type of restricted stock [1]. Approval Process and Compliance - The plan has undergone necessary approval procedures, including reviews by the Board of Directors and the Compensation and Assessment Committee [2][3]. - The list of eligible participants was publicly disclosed, and no objections were raised during the public notice period [2][10]. - The plan has received approval from the shareholders' meeting, allowing the Board to determine the grant date and execute necessary actions [2][11]. Grant Conditions - The grant conditions include the absence of negative audit opinions on financial reports and compliance with relevant laws and regulations [4][5]. - The eligible participants must not have been deemed inappropriate candidates by regulatory authorities within the last 12 months [4][5]. Vesting Schedule - The vesting of the granted shares will occur in three phases: 20% after 12 months, 30% after 24 months, and 50% after 36 months from the grant date [8]. - The vesting schedule is designed to align the interests of the participants with the company's long-term performance [8]. Financial Impact and Accounting Treatment - The fair value of the restricted stock will be calculated using the Black-Scholes model, and the associated costs will be amortized over the vesting period [11][12]. - The estimated total expense for the stock incentive plan will impact the company's net profit during the vesting period [12][13]. Legal Compliance - The legal opinion confirms that the grant has received necessary approvals and complies with relevant regulations [13].

Core Viewpoint - The company has announced an adjustment to the grant price of its 2024 restricted stock incentive plan, reducing it from 15.36 CNY per share to 15.29 CNY per share due to the completion of its annual profit distribution [3][4][5]. Summary by Sections Approval Process - The company held meetings to approve the 2024 restricted stock incentive plan and its related proposals, including the adjustment of the grant price [2][3]. - The board of directors and the supervisory committee have verified and approved the list of incentive recipients [2]. Adjustment Details - The adjustment was made following the completion of the 2024 annual profit distribution, where shareholders received a cash dividend of 0.735 CNY for every 10 shares held [3][5]. - The adjustment formula used was P = P0 - V, where P0 is the original grant price and V is the cash dividend per share [3][4]. Impact of Adjustment - The adjustment of the grant price is in compliance with relevant regulations and will not materially affect the company's financial status or operating results [5][6]. - Both the remuneration and assessment committee and the supervisory committee have agreed that the adjustment process is legal and does not harm the interests of the company or its shareholders [5][6]. Legal Opinion - The legal opinion confirms that the adjustment has received the necessary approvals and complies with applicable laws and regulations [6].

上海联影医疗科技股份有限公司董事会薪酬与考核委员会 （1）最近 12 个月内被证券交易所认定为不适当人选； （2）最近 12 个月内被中国证监会及其派出机构认定为不适当人选； （3）最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政 处罚或者采取市场禁入措施； 关于公司 2025 年限制性股票激励计划 （4）具有《公司法》规定的不得担任公司董事、高级管理人员情形的； （5）法律法规规定不得参与上市公司股权激励的； （6）中国证监会认定的其他情形。 首次授予激励对象名单（首次授予日）的核查意见 上海联影医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日 召开第二届董事会 2025 年第三次会议，审议通过了《关于向公司 2025 年限制 性股票激励计划激励对象首次授予限制性股票的议案》。 公司董事会薪酬与考核委员会依据《中华人民共和国公司法》（以下简称 "《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公 司股权激励管理办法》（以下简称"《管理办法》"）、《上海证券交易所科创板股 票上市规则》（以下简称"《上市规则》"）、《科创板上市公司自律监管指南 ...

Group 1 - The board of directors of Shanghai United Imaging Healthcare Co., Ltd. held its 22nd meeting on August 25, 2025, with all 9 directors participating in the voting [1] - The meeting approved the adjustment of the initial grant price for the 2025 restricted stock incentive plan from 95 yuan per share to 94.92 yuan per share, with a unanimous vote of 9 in favor [2] - The board also approved the initial grant of 4.4713 million restricted shares to 1,368 incentive targets, with the grant date set for August 25, 2025, at the adjusted price of 94.92 yuan per share [3]

Core Viewpoint - The legal opinion letter from Beijing Zhonglun (Shanghai) Law Firm confirms the compliance and approval of Jiangsu Saifutian Group Co., Ltd.'s 2025 Restricted Stock Incentive Plan adjustments and grants, ensuring alignment with relevant laws and regulations [1][2][8]. Group 1: Approval and Authorization - The board's compensation and assessment committee believes that the implementation of the incentive plan will enhance the company's incentive mechanism and align employee and shareholder interests, promoting long-term sustainable development [3][4]. - The adjustments to the incentive plan include a reduction in the number of recipients from 86 to 84 and a decrease in the total number of restricted shares from 3 million to 2.93 million due to two recipients voluntarily giving up their shares [6][8]. Group 2: Granting Details - The grant date for the restricted stock is set for August 25, 2025, which complies with the stipulated timeline following the shareholders' meeting approval [8][10]. - The conditions for granting the restricted stock include the absence of negative audit opinions and compliance with relevant laws, confirming that both the company and the recipients meet the necessary criteria [10][11]. Group 3: Conclusion - The legal opinion concludes that all necessary approval and authorization procedures have been followed, and the adjustments and grants are in accordance with the applicable laws and regulations [12].

Core Viewpoint - The company has announced the achievement of conditions for the first unlock period of the second batch of restricted stock incentive plan, allowing three eligible participants to unlock a total of 97,350 shares, representing 0.0195% of the company's total share capital [1][10]. Group 1: Incentive Plan Approval and Implementation - The board of directors approved the proposal regarding the achievement of conditions for the first unlock period of the second batch of the restricted stock incentive plan during the ninth board meeting [2]. - The company has completed the registration of the restricted stock for the second batch, granting 295,000 shares to three participants at a price of 5.36 yuan per share, with the shares listed on April 26, 2023 [5][10]. Group 2: Conditions for Unlocking Shares - The conditions for unlocking the shares include the company not receiving any negative audit opinions and meeting performance assessment criteria, such as a net profit growth rate of at least 10% compared to the industry average [9][10]. - The specific performance metrics for the year 2022 include a net profit growth rate of 18.89% and a cash return on net assets of 17%, both exceeding the industry averages [9]. Group 3: Legal and Compliance Aspects - The company has obtained necessary approvals and authorizations for the unlocking of shares, ensuring compliance with relevant laws and regulations, including the Company Law and Securities Law [11]. - The legal opinion confirms that the unlocking of shares meets all required conditions and does not harm the interests of the company or its shareholders [11].

Core Viewpoint - Jiangsu Hualv Biological Technology Group Co., Ltd. announced the cancellation of 180,000 shares of unvested restricted stock from its 2023 incentive plan, which will not materially affect the company's financial status or operational results [1][3][4]. Summary by Sections Incentive Plan Approval Process - The company conducted necessary approvals for the 2023 restricted stock incentive plan, which included independent directors' agreement and the authorization from the second extraordinary general meeting of shareholders in 2023 [1][2]. Details of Canceled Restricted Stock - A total of 180,000 shares of restricted stock that were granted but not yet vested will be canceled as per the regulations outlined in the incentive plan and relevant management guidelines [3][4]. Impact of Canceled Restricted Stock - The cancellation of these shares will not have a substantial impact on the company's financial condition or operational performance, nor will it affect the stability of the management team or the ongoing implementation of the stock incentive plan [4]. Supervisory Board Opinion - The supervisory board concluded that the cancellation process complied with legal and regulatory requirements and did not harm the interests of the company or its shareholders, particularly minority shareholders [4]. Legal Opinion Conclusion - The legal opinion from Shanghai Jintiancheng Law Firm confirmed that the company has obtained necessary approvals and followed appropriate procedures regarding the adjustments and cancellations related to the incentive plan [4][5].

公司简称：神农集团 证券代码：605296 上海荣正企业咨询服务（集团）股份有限公司 关于 云南神农农业产业集团股份有限公司 之 独立财务顾问报告 目 录 一、释义 在本独立财务顾问报告中，除非特别载明，以下简称具有如下含义： 云南神农农业产业集团股份有限公司（含合并报表分子 神农集团、公司、上市公司 指 公司） 本激励计划、限制性股票激励计 云南神农农业产业集团股份有限公司 2025 年限制性股 指 划、股权激励计划 票激励计划（草案） 公司根据本激励计划规定的条件和价格，授予激励对象 一定数量的公司股票，该等股票设置一定期限的限售期， 限制性股票 指 在达到本激励计划规定的解除限售条件后，方可解除限 售流通 按照本激励计划规定，获得限制性股票的公司董事、高 激励对象 指 级管理人员、中层管理人员及核心骨干 公司向激励对象授予限制性股票的日期，授予日必须为 授予日 指 交易日 授予价格 指 公司授予激励对象每一股限制性股票的价格 激励对象根据本激励计划获授的限制性股票被禁止转 限售期 指 让、用于担保、偿还债务的期间 本激励计划规定的解除限售条件成就后，激励对象持有 解除限售期 指 的限制性股票可以解除限售 ...

Core Viewpoint - The legal opinion from Beijing Deheng Law Firm confirms the validity of the cancellation of unvested restricted stock awards under the 2024 incentive plan of Jinan Hengyu Environmental Technology Co., Ltd, following the departure of certain incentive recipients [1][6][9]. Group 1: Approval and Authorization - The company has obtained necessary approvals and authorizations for the cancellation of unvested restricted stock awards as per the relevant regulations and internal governance documents [6][9]. - The board of directors and the supervisory board have passed resolutions regarding the incentive plan and the cancellation of certain stock awards [4][6]. Group 2: Reasons for Cancellation - The cancellation of restricted stock awards is due to the departure of three incentive recipients, who no longer meet the eligibility criteria, resulting in a total of 70,000 shares being rendered void [6][7]. - The incentive plan stipulates that unvested stock awards are forfeited if the recipient leaves the company for any reason, including resignation or termination [6][7]. Group 3: Details of the Cancellation - A total of 644,464 shares of restricted stock have been canceled due to failure to meet performance criteria set in the incentive plan, with 574,464 shares specifically linked to unmet performance conditions for the first vesting period [8][9]. - The performance assessment for the incentive plan is based on revenue and net profit growth compared to the previous year, with specific targets established for each assessment period [7][8].

上海君澜律师事务所 关于 云南神农农业产业集团股份有限公司 之 法律意见书 二〇二五年八月 上海君澜律师事务所 法律意见书 上海君澜律师事务所 关于云南神农农业产业集团股份有限公司 法律意见书 致：云南神农农业产业集团股份有限公司 上海君澜律师事务所（以下简称"本所"）接受云南神农农业产业集团股 份有限公司（以下简称"公司"或"神农集团"）的委托，根据《上市公司股 权激励管理办法》（以下简称"《管理办法》"）及《云南神农农业产业集团 股份有限公司 2025 年限制性股票激励计划》（以下简称"《激励计划》"或 "本次激励计划"）的规定，就神农集团本次激励计划向激励对象首次授予限 制性股票的相关事项（以下简称"本次授予"）出具本法律意见书。 对本法律意见书，本所律师声明如下： （一）本所律师依据《中华人民共和国证券法》《律师事务所从事证券法 律业务管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定及 本法律意见书出具日以前已经发生或者存在的事实，严格履行了法定职责，遵 循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保证本法律意见所认 定的事实真实、准确、完整，所发表的结论性意见合法、准确，不存在虚假 ...